Recombinant Oncolytic Virus Composition for Tumor APC Conversion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatment strategies, including dendritic cell-based interventions and oncolytic virus therapies, are limited by tumor tissue heterogeneity and the downregulation of antigen presentation, leading to ineffective TIL therapy and suboptimal viral delivery to cancer cells, which hinders immune response activation and tumor clearance.
Innovation Solution
Administering recombinant oncolytic viruses expressing trimeric OX40L and IL-12, optionally with a PD-1 inhibitor, to convert tumor cells into antigen-presenting cells (APCs), enhancing their antigen presentation capabilities and promoting TIL infiltration, expansion, and activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dendritic cell-based interventions or oncolytic virus therapies are used to enhance antigen presentation, then T cell activation is improved, but tumor tissue heterogeneity and downregulation of antigen presentation lead to ineffective therapy and suboptimal viral delivery
Solution Approach 1:
The patent modifies the parameters of tumor cells by introducing recombinant oncolytic viruses that express MHC class I and II molecules, co-stimulatory molecules (CD80, CD86), and cytokines (IL-12, OX40L). These parameter changes convert tumor cells into effective antigen-presenting cells, overcoming the limitation of tumor tissue heterogeneity and enabling reliable therapeutic efficacy across diverse tumor types.
Solution Approach 2:
The patent enables tumor cells to serve themselves as antigen-presenting cells. By infecting tumor cells with recombinant oncolytic viruses, the tumor cells themselves begin to express the necessary MHC molecules and co-stimulatory molecules to present their own antigens to T cells, eliminating the need for external dendritic cell interventions and adapting to various tumor microenvironments.
2Adaptability or versatility
If tumor cells are forced to acquire antigen presentation capabilities through transfection, then DC-based intervention limitations are overcome, but the complexity of ensuring proper MHC and co-stimulatory molecule expression increases
Solution Approach 1:
The patent merges multiple functions into a single recombinant oncolytic virus vector. The virus simultaneously delivers genes for MHC class I and II molecules, co-stimulatory molecules (CD80, CD86), and cytokines (IL-12, OX40L) to tumor cells. This consolidation simplifies the transfection process while ensuring coordinated expression of all necessary components for effective antigen presentation and T cell activation.
Solution Approach 2:
The recombinant oncolytic virus acts as an intermediary carrier that facilitates the introduction of multiple genetic elements into tumor cells. The virus serves as a natural delivery vehicle that can accommodate and express multiple transgenes simultaneously, reducing the complexity associated with traditional transfection methods and ensuring proper expression of MHC and co-stimulatory molecules.
3Reliability
If multiple signals are required for T cell activation (MHC/antigen interaction and co-stimulatory molecule interaction), then proper T cell activation is achieved, but the requirement for multiple molecular expressions in tumor cells increases complexity
Solution Approach 1:
The recombinant oncolytic virus merges multiple gene expression functions into a single therapeutic intervention. It simultaneously expresses MHC class I and II molecules for antigen presentation, co-stimulatory molecules (CD80, CD86) for second signal delivery, and cytokines (IL-12, OX40L) for T cell differentiation and activation. This consolidation ensures all necessary molecular signals are provided to achieve reliable T cell activation while simplifying the overall therapeutic approach.
Data Source
AI summary
A recombinant armed oncolytic virus composition for conversion of tumor cells into APCs, specifically herpes simplex oncolytic virus composition. The oncolytic virus composition infects tumor cells and expresses trimeric OX40L and IL-12 and optionally a PD-1 inhibitor. Also provided is the use of the oncolytic virus composition for enhancing antigen presentation of tumor cells, and for enhancing the anti-tumor effect of a tumor infiltrating lymphocyte (TIL) in cancer therapy. Further provided are a pharmaceutical composition, a kit, and a combination product for the methods and uses.